Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.08 USD | +3.61% | +12.30% | +14.48% |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
Apr. 23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
Business Summary
Number of employees: 297
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Medicines
100.0
%
| 220 | 100.0 % | 270 | 100.0 % | +22.74% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Bermuda
100.0
%
| 220 | 100.0 % | 270 | 100.0 % | +22.74% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 15-06-30 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 15-06-30 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 18-04-30 |
Chad Morin
CMP | Compliance Officer | - | 20-09-30 |
John Paolini
CTO | Chief Tech/Sci/R&D Officer | 59 | 16-07-31 |
Rachel Frank
IRC | Investor Relations Contact | - | - |
General Counsel | - | 20-07-31 | |
Ross Moat
PRN | Corporate Officer/Principal | 43 | 18-12-31 |
Martina Struck
LAW | General Counsel | - | 17-12-31 |
Melissa Manno
HRO | Human Resources Officer | - | 16-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-09-30 |
Barry D. Quart
BRD | Director/Board Member | 67 | 15-09-30 |
Thomas Malley
BRD | Director/Board Member | 55 | 16-11-30 |
Richard Levy
BRD | Director/Board Member | 66 | 19-03-03 |
Kim Popovits
BRD | Director/Board Member | 65 | 18-01-31 |
G. Cole
BRD | Director/Board Member | 68 | 20-07-26 |
Stephen Biggar
BRD | Director/Board Member | 53 | 15-09-30 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 15-06-30 |
Tracey McCain
BRD | Director/Board Member | 56 | 18-01-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 16,057,618 | 0 | 0 | 54.58 % |
Stock B | 1 | 12,781,964 | 0 | 0 | |
Stock C | 1 | 1,795,158 | 0 | 0 | |
Stock D | 1 | 40,305,405 | 38,721,005 ( 96.07 %) | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.48% | 1.42B | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- KNSA Stock
- Company Kiniksa Pharmaceuticals, Ltd.